Europäische Union - Deutsch - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. siehe abschnitte 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.

Europäische Union - Deutsch - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - antineoplastische mittel - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed  after at least one prior line of systemic therapy.

Europäische Union - Deutsch - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - antineoplastische mittel - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).

Europäische Union - Deutsch - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - andere dermatologische präparate - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

incyte biosciences international sàrl - ponatinibum - filmtabletten - ponatinibum 15 mg zu ponatinibi hydrochloridum, excipiens pro compresso dunst. - antineoplastische - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

incyte biosciences international sàrl - ponatinibum - filmtabletten - ponatinibum 45 mg bis ponatinibi hydrochloridum, excipiens pro compresso dunst. - antineoplastische - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

incyte biosciences international sàrl - ponatinibum - filmtabletten - ponatinibum 30 mg zu ponatinibi hydrochloridum, excipiens pro compresso dunst. - antineoplastische - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

incyte biosciences international sàrl - pemigatinibum - tabletten - pemigatinibum 4.5 mg, cellulosum microcristallinum, carboxymethylamylum natricum a corresp. natrium 0.176 mg, magnesii stearas, pro compresso. - cholangiocarcinome - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

incyte biosciences international sàrl - pemigatinibum - tabletten - pemigatinibum 9 mg, cellulosum microcristallinum, carboxymethylamylum natricum a corresp. natrium 0.352 mg, magnesii stearas, pro compresso. - cholangiocarcinome - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

incyte biosciences international sàrl - pemigatinibum - tabletten - pemigatinibum 13.5 mg, cellulosum microcristallinum, carboxymethylamylum natricum a corresp. natrium 0.528 mg, magnesii stearas, pro compresso. - cholangiocarcinome - synthetika